Navigation Links
Webcast Alert: Isis Pharmaceuticals' 2010 Financial Results and Highlights Conference Call
Date:2/14/2011

CARLSBAD, Calif., Feb. 14, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:What:

Isis Pharmaceuticals' 2010 Financial Results and HighlightsWhen:

Monday, February 28, 2011 at 4:30 p.m. ET / 1:30 p.m. PTWhere:

www.isispharm.comHow:

Live on the Internet.  Simply log onto our Web site listed above. If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 24 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs as well as all aspects of antisense drug discovery, development and manufacturing.  Additional information about Isis is available at www.isispharm.com.


'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Talecris Biotherapeutics Announces Teleconference and Webcast Information for Special Meeting of Shareholders
2. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
3. Amgen Announces Webcast of 2010 Fourth Quarter and Full Year Financial Results
4. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2010 Earnings Conference Call
5. Regenicin CEO to Participate in Live Webcast at OneMedForum Business Development and Finance Conference, January 11th at 4:00 PM PST
6. Gen-Probe to Webcast Presentation at the 29th Annual J.P. Morgan Healthcare Conference
7. Gentiva® Health Services Schedules 2011 Outlook Conference Call and Webcast for Thursday, December 16, 2010
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
9. Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data
10. Palatin Technologies, Inc. to Report Fiscal Year 2011 First Quarter Results; Teleconference and Webcast to be Held on November 16, 2010
11. Hikma Expands its Global Injectables Business - Live Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... & Rockville, MD (PRWEB) July 29, 2014 ... Inc. (ITI), a vaccine pioneer in the biotechnology ... services firm Newport Coast Securities, Inc. to explore ... is commercializing LAMP-vax technology, a breakthrough vaccine platform ... and immunotherapy market. The company exclusively licensed the ...
(Date:7/29/2014)... 29, 2014  Sigma-Aldrich Corporation (NASDAQ: SIAL ... increased its investment in Green Chemistry and donated more ... last year, the Company announced Monday in its new ... the World? The report comes in ... being a responsible corporate citizen, including recognition for the ...
(Date:7/29/2014)...  United Therapeutics Corporation (NASDAQ: ... for the second quarter ended June 30, 2014. ... our medicines are reaching increasing numbers of ... said Martine Rothblatt, Ph.D., United Therapeutics, Chairman ... this quarter of our extended-release tablet called ...
(Date:7/29/2014)... 29, 2014 Eppendorf Centrifuge 5427 ... selection. Eppendorf 5427 R is geared towards high-end applications ... it is targeted towards work requiring high sample throughput. ... as it compliments their extensive 16, 48, and 64 ... microcentrifuge tubes, PCR tubes, PCR strip tubes, and more. ...
Breaking Biology Technology:Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2
... energy company, BioPower Systems (BPS), today announced that the ... O,Brien MP, has awarded the company conditional funding support ... Program. The funding will be applied towards ... bioWAVE ocean wave energy system at a grid-connected site ...
... Medical Center researchers could still be close to giving heart ... The "LateTIME" trial was a study of adult ... to have the ability to improve heart function after an ... the attack. Results were released this week ...
... Palatin Technologies, Inc. (NYSE Amex: ... peptide therapeutics for the treatment of diseases with ... announced that Dr. Carl Spana, President and Chief ... Area Partnerships conference on Thursday, December 1, 2011.  ...
Cached Biology Technology:BioPower Systems Awarded $5 Million from Victorian Government 2BioPower Systems Awarded $5 Million from Victorian Government 3Post Heart Attack Recovery Not Aided By Stem Cell Injections, But Trial Demonstrates Promise 2Palatin Technologies to Present at Windhover's Therapeutic Area Partnerships Conference 2
(Date:7/29/2014)... in locomotion. Swimming microorganisms, such as bacteria and spermatozoa, ... the viscous forces exerted by the surrounding fluid. ... scientists have found that the direction of propulsion made ... by a viscoelastic fluid. These findings have been published ... the Alternative Energies and Atomic Energy Commission (CEA), in ...
(Date:7/29/2014)... wildfires that have been plaguing the Northern Territories in ... Great Lakes in the U.S. continue on. NASA,s ... Resolution Imaging Spectroradiometer, MODIS, instrument on July 26, 2014. ... outlined in red. Copious amount of smoke are drifting ... havoc for residents of Yellowknife. Fire has caused ...
(Date:7/29/2014)... the University of Kent has shown for the first ... a breakthrough that could have a major impact on ... of Biosciences uncovered the mechanism whereby the physical properties ... actin filaments are ,fine-tuned, to undertake different functions. ... completely stable, providing a framework for the cell, others ...
Breaking Biology News(10 mins):Optimum inertial self-propulsion design for snowman-like nanorobot 2
... GOCE satellite from the Plesetsk cosmodrome in northern Russia had ... due to an anomaly identified in one of the units ... stage (Breeze KM ). The correction of the problem ... perform this operation, it will be necessary to de-mate the ...
... physician-geneticist and leader of the Human Genome Project, has ... the Inamori International Center for Ethics and Excellence at ... and Kyoto Prizes for science, technology, philosophy and the ... ethical leaders. It is presented annually to an individual ...
... de los Alimentos (Institute of Nutrition and Food Technology) ... doing research into the positive effects of Mediterranean diet,s ... is a new research line about pancreatic cancer cells. ... points out that in the study ,Influence of the ...
Cached Biology News:Leader of Human Genome Project honored with the Inamori Ethics Prize 2New studies on the Mediterranean diet confirm its effectiveness for chronic disease prevention 2
... The Label IT siRNA Tracker Intracellular Localization ... directly label and deliver siRNA, of your ... for in vitro tracking experiments. Subcellular localization ... can be monitored following introduction of the ...
... The Label IT siRNA Tracker Intracellular ... provides a straight forward approach to ... your design, in an efficient yet ... experiments. Subcellular localization and functional inhibition ...
... and reproducible immunoprecipitation (IP) by using a 96 ... than regular IPs, which are problematic with regards ... the agarose bed. The binding of the antibody/antigen ... elution of the immune complex can occur with ...
... The Yeast Oligo Microarray Kit (V2), ... to simultaneously characterize expression of many ... gene activity during important biological processes. ... representing 6,256 known ORFs from the ...
Biology Products: